1. Home
  2. ATAI vs LPAA Comparison

ATAI vs LPAA Comparison

Compare ATAI & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • LPAA
  • Stock Information
  • Founded
  • ATAI 2018
  • LPAA 2024
  • Country
  • ATAI Germany
  • LPAA United States
  • Employees
  • ATAI N/A
  • LPAA N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • LPAA
  • Sector
  • ATAI Health Care
  • LPAA
  • Exchange
  • ATAI Nasdaq
  • LPAA Nasdaq
  • Market Cap
  • ATAI 282.6M
  • LPAA 296.1M
  • IPO Year
  • ATAI 2021
  • LPAA 2024
  • Fundamental
  • Price
  • ATAI $1.41
  • LPAA $10.32
  • Analyst Decision
  • ATAI Strong Buy
  • LPAA
  • Analyst Count
  • ATAI 3
  • LPAA 0
  • Target Price
  • ATAI $10.50
  • LPAA N/A
  • AVG Volume (30 Days)
  • ATAI 1.4M
  • LPAA 35.0K
  • Earning Date
  • ATAI 05-19-2025
  • LPAA 01-01-0001
  • Dividend Yield
  • ATAI N/A
  • LPAA N/A
  • EPS Growth
  • ATAI N/A
  • LPAA N/A
  • EPS
  • ATAI N/A
  • LPAA N/A
  • Revenue
  • ATAI $308,000.00
  • LPAA N/A
  • Revenue This Year
  • ATAI $65.58
  • LPAA N/A
  • Revenue Next Year
  • ATAI N/A
  • LPAA N/A
  • P/E Ratio
  • ATAI N/A
  • LPAA $48.18
  • Revenue Growth
  • ATAI N/A
  • LPAA N/A
  • 52 Week Low
  • ATAI $1.03
  • LPAA $9.66
  • 52 Week High
  • ATAI $2.57
  • LPAA $10.70
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 44.57
  • LPAA N/A
  • Support Level
  • ATAI $1.36
  • LPAA N/A
  • Resistance Level
  • ATAI $1.54
  • LPAA N/A
  • Average True Range (ATR)
  • ATAI 0.09
  • LPAA 0.00
  • MACD
  • ATAI -0.00
  • LPAA 0.00
  • Stochastic Oscillator
  • ATAI 0.00
  • LPAA 0.00

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

About LPAA Launch One Acquisition Corp. Class A Ordinary shares

Launch One Acquisition Corp is a blank check company.

Share on Social Networks: